NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price, Forecast & News

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) announced its quarterly earnings data on Friday, February, 14th. The company reported ($0.45) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.03. View Spring Bank Pharmaceuticals' Earnings History.

Spring Bank Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Spring Bank Pharmaceuticals.

6 brokers have issued 1 year price targets for Spring Bank Pharmaceuticals' stock. Their forecasts range from $1.50 to $29.00. On average, they anticipate Spring Bank Pharmaceuticals' share price to reach $11.84 in the next twelve months. This suggests a possible upside of 929.6% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.

Press coverage about SBPH stock has trended somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 29,500 shares, an increase of 21.4% from the January 15th total of 24,300 shares. Based on an average daily volume of 296,800 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the company's shares are short sold. View Spring Bank Pharmaceuticals' Current Options Chain.

Some companies that are related to Spring Bank Pharmaceuticals include Onconova Therapeutics (ONTX), CTI BioPharma (CTIC), Trevena (TRVN), Eyenovia (EYEN), Chembio Diagnostics (CEMI), Entasis Therapeutics (ETTX), ASLAN PHARMACEU/ADR (ASLN), Cumberland Pharmaceuticals (CPIX), Catabasis Pharmaceuticals (CATB), CNS Pharmaceuticals (CNSP), Tiziana Life Sciences (TLSA), Advaxis (ADXS), NewLink Genetics (NLNK), Soligenix (SNGX) and SCYNEXIS (SCYX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), Associated British Foods (ABF), Chaarat Gold (CGH), Apollo Global Management (APO), Strongbridge Biopharma (SBBP), China Unicom (Hong Kong) (CHU) and Ciena (CIEN).

(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

Spring Bank Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (5.78%), Tiedemann Advisors LLC (2.58%), Renaissance Technologies LLC (1.22%), Hikari Power Ltd (0.80%) and Parsons Capital Management Inc. RI (0.56%). Company insiders that own Spring Bank Pharmaceuticals stock include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View Institutional Ownership Trends for Spring Bank Pharmaceuticals.

SBPH stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Parsons Capital Management Inc. RI, Hikari Power Ltd and Tiedemann Advisors LLC. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

SBPH stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBPH stock can currently be purchased for approximately $1.15.

Spring Bank Pharmaceuticals has a market capitalization of $18.95 million. The company earns $-24,100,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.View Additional Information About Spring Bank Pharmaceuticals.

The official website for Spring Bank Pharmaceuticals is http://springbankpharm.com/.

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]